![Niklas Axelsson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 605 $ al 31/05/2026
Niklas Axelsson is currently Chief Financial Officer at Diamyd Medical AB since 2025.
Formerly, Mr. Axelsson was Chief Financial Officer at Sprint Bioscience AB. Education includes an undergraduate degree from Stockholm School of Economics.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/08/2025 | 5.000 ( 0 % ) | 605 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| DIAMYD MEDICAL AB | Director Financiero/CFO | 01/01/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| SPRINT BIOSCIENCE AB | Director Financiero/CFO | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Stockholm School of Economics
 Stockholm School of Economics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sprint Bioscience AB
 Sprint Bioscience AB Pharmaceuticals: MajorHealth Technology Develops medicines in the field of cancer and metabolism | Health Technology |
Diamyd Medical AB
 Diamyd Medical AB Pharmaceuticals: MajorHealth Technology Develops precision medicine drugs for type 1 diabetes and other forms of autoimmune diabetes | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
